Linagliptin/Metformin Hydrochloride

Adalvo has commenced pivotal bioequivalence (BE) studies for its generic Linagliptin and Metformin fixed-dose combination (FDC) tablet. Coming soon after the company received DCP approval and marketing authorization for its Linagliptin 5mg film-coated tablet, the study is a key milestone for one of the most commercially relevant oral diabetes therapies in the global generics market. Developed as a generic of Jentadueto, Linagliptin and Metformin FDC is indicated for the treatment of type 2 diabetes mellitus in adults. Linagliptin blocks the DPP-4 enzyme, stimulating insulin production after meals. Metformin reduces the amount of glucose released by the liver, enabling the body to use insulin more effectively. Combined in a single tablet, they deliver complementary glycaemic control without the risk of hypoglycaemia. Type 2 diabetes represents one of the most urgent and fast-growing challenges in global healthcare. A 2025 report from the International Diabetes Federation estimates that 589 million adults — 11.1% of the world's population — are currently living with diabetes. By 2050, that figure is projected to reach 853 million. In 2024 alone, the disease caused 3.4 million deaths and accounted for over $1 trillion in global health expenditure. Low- and middle-income countries carry 80% of the diabetes burden, and over half of those affected in these regions remain undiagnosed. As diagnostic coverage improves, patient numbers will rise sharply — driving significant demand for affordable oral therapies. According to IQVIA, the total addressable market for Linagliptin and Metformin was $878 million in 2025. With cases of type 2 diabetes set to keep rising, the commercial opportunity for licensing partners is substantial and growing. To discuss licensing opportunities for Linagliptin and Metformin FDC, or to explore Adalvo's full diabetes portfolio, get in touch.

TUESDAY, March 24, 2026 — TrumpRx , the president's discount program for prescription drugs, is adding three more products to its site as it continues efforts to lower drug prices. The newly added medicines include two for type 2 diabetes , Jentadueto and Jentadueto XR , and one for chronic obstructive pulmonary disease ( COPD ), Striverdi Respimat . All three are made by German drugmaker Boehringer Ingelheim, and officials say the price cuts are steep. The diabetes drugs, which usually cost about $525, are listed on TrumpRx starting around $55. The COPD inhaler drops from about $276 to $35, according to the White House. “Those are pretty significant discounts,” Ben Link , a contributor at 46brooklyn, a nonprofit group that tracks drug prices, told NBC News . Even so, Link noted that one of the drugs, Jentadueto, already has a lower-cost generic version. Patients pay about $25 to $35 for that option at the pharmacy now. Still, he said, the TrumpRx price is "competitive." The TrumpRx website launched in January as part of a broader push by President Donald Trump to bring down drug costs. Experts say the program is limited, however. The discounts are only for people paying cash. They can’t be used with insurance and don’t count toward deductibles. “The goal was not actually some massive reach,” Chris Klomp , a senior U.S. Health and Human Services official, said at an event last week. He said the program was not designed as a full solution to high drug prices. So far, TrumpRx lists fewer than 60 drugs, mostly brand-name medicines. Many already have cheaper generic versions. Similar discounts can also be found on other sites. It’s also unclear how much the program is actually being used. A recent survey by KFF found that about 1 in 3 people who take prescription drugs had heard of TrumpRx. But only 7% said they had visited the site to look at prices. Among folks taking GLP-1 drugs, about 16% said they checked it out. NBC News said that the White House has not shared how many people have used the website since it launched. Even with insurance, however, many Americans still struggle to afford medications. A recent poll from West Health-Gallup found that about a third of adults made trade-offs to afford health care in the past year, including skipping or cutting back on meds. Sources NBC News, March 20, 2026